European Society for Medical Oncology (ESMO) shared on LinkedIn:
“ESMO26: Novel Targeted Therapies, including the dual EZH1/2 inhibitor epsametostat and the pan-CLK/DYRK inhibitor cirtuvivint, alongside lifileucel, the developmental TIL therapy, show encouraging antitumor activity in early-phase sarcoma clinical trials, but their investigation in larger patient cohorts with longer follow-up is essential, as discussed by Katarzyna Kozak.
About New Findings in Sarcoma Treatment
Recent findings presented at the ESMO Congress 2026 highlight promising advancements in the treatment of rare and aggressive forms of sarcoma, focusing on novel targeted and cellular therapies. Despite previous setbacks with certain epigenetic inhibitors, research into targeting EZH1/2 continues to offer renewed hope for patients with epithelioid sarcoma.
In a pivotal phase II study, the dual EZH1/2 inhibitor epsametostat demonstrated a remarkable objective response rate of 40.0% and a median progression-free survival of 13.1 months in evaluable epithelioid sarcoma patients.
Experts note that these efficacy outcomes compare favorably with standard chemotherapy, though longer follow-up remains essential to carefully monitor safety profiles and potential secondary hematological risks.
Additionally, clinical trials exploring alternative splicing modulation via the pan-CLK/DYRK inhibitor cirtuvivint showed intriguing disease control rates, particularly displaying a 3-month progression-free survival rate of 85% in patients with solitary fibrous tumors. These results point toward potential avenues for heavily pretreated patient groups with limited alternatives.
Cellular approaches, specifically tumor-infiltrating lymphocyte (TIL) therapy using lifileucel, also displayed encouraging feasibility and efficacy in aggressive subtypes like undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma.
Looking forward, specialists emphasize that addressing the biological heterogeneity of rare cancers will require subtype-specific strategies, comprehensive molecular profiling, and tumor-agnostic approaches to expand treatment access. Continued clinical investigations and broader trial developments remain crucial to turning these early-phase successes into durable, long-lasting clinical outcomes for sarcoma patients.
You can also read: OncoDaily Grand Rounds at ESMO 2026: All You Need to Know About Sarcoma
